Alliance for Pandemic Preparedness

February 3, 2021

Azithromycin in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial

Category:

Topic:

Keywords (Tags):

A randomized open-label trial (RECOVERY) of azithromycin for COVID-19 found no significant differences in survival (rate ratio=0.97), duration of hospital stay (median 10 vs 11 days), or proportion of patients discharged from the hospital alive within 28 days (RR=1.04) between participants receiving azithromycin versus usual care. Among patients not receiving mechanical ventilation at baseline, no significant difference was observed in the proportion of patients meeting composite endpoints of mechanical ventilation or death (RR=0.95). 

Abaleke et al. (Feb 3, 2021). Azithromycin in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial. The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00149-5/fulltext